NasdaqGS:XERSPharmaceuticals
Xeris Biopharma (XERS) Turns Trailing Profitability Into Test Of Bullish Growth Narrative
Xeris Biopharma Holdings (XERS) closed out FY 2025 with fourth quarter revenue of US$85.8 million, basic EPS of US$0.07, and net income of US$11.1 million. On a trailing twelve month basis, revenue was US$291.8 million and basic EPS was US$0.00, reflecting a small net profit of US$0.6 million. The company has seen revenue move from US$203.1 million and basic EPS of a US$0.37 loss on a trailing basis in Q4 2024 to US$291.8 million and essentially breakeven EPS by Q4 2025. That shift toward...